BPC-157
Also known as: Body Protection Compound-157, PL-10, PL 14736
Healing & Recovery~1419.5 Da
A synthetic pentadecapeptide derived from a protective protein found in human gastric juice, investigated in preclinical research for tissue repair and gastrointestinal protection.
BPC-157, or Body Protection Compound-157, is one of the most widely discussed peptides in regenerative medicine research today. Originally isolated from a protective protein found in human gastric juice, this 15-amino-acid synthetic peptide has generated substantial scientific interest across a range of preclinical studies. Researchers have investigated its potential effects on tissue repair, gastrointestinal protection, and wound healing in animal models. While BPC-157 is not FDA-approved for any medical condition, its presence in the peptide therapy landscape continues to grow as more providers offer it through compounding pharmacy channels.
What Is BPC-157?
BPC-157 is a pentadecapeptide, meaning it consists of a chain of 15 amino acids. It is derived from body protection compound (BPC), a protein that occurs naturally in human gastric juice at very low concentrations. What makes BPC-157 unusual among peptides is its reported stability in gastric acid, an environment that typically degrades peptide structures rapidly. This stability has made it a particular subject of interest in gastrointestinal research. The peptide has a molecular weight of approximately 1419.5 Da and does not have a known specific receptor target, which has made its mechanism of action a topic of ongoing scientific investigation.
How BPC-157 Is Studied
The vast majority of BPC-157 research has been conducted in animal models, primarily rodents. Published preclinical studies have explored its effects on tendon-to-bone healing, muscle injury repair, ligament recovery, bone fracture healing, and gastrointestinal mucosal protection. Researchers have also studied BPC-157 in models of inflammatory bowel conditions, nerve damage, and vascular injury. Some studies have used both systemic injection and local application routes. It is important to note that while the volume of animal research is extensive, large-scale randomized controlled human clinical trials for BPC-157 remain very limited. The translation of animal findings to human outcomes is uncertain, and conclusions drawn from preclinical data should be interpreted with appropriate caution.
Proposed Mechanisms of Action
Several biological pathways have been proposed to explain the effects observed in BPC-157 research. These include modulation of growth factor expression, particularly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which play roles in blood vessel formation and tissue repair. BPC-157 has also been studied for its interactions with the nitric oxide (NO) system, which is involved in blood flow regulation and inflammation. Other proposed mechanisms include effects on the FAK-paxillin pathway related to cell migration, and potential interactions with dopaminergic and serotonergic systems. However, none of these mechanisms have been conclusively established in human studies, and the precise pharmacological profile of BPC-157 remains an active area of investigation.
Common Goals Associated with BPC-157
In the context of peptide therapy clinics, BPC-157 is most frequently discussed in relation to recovery and tissue repair goals. Patients seeking support for musculoskeletal injuries, joint discomfort, and post-surgical recovery often encounter BPC-157 in their research. Some providers also discuss it in the context of gastrointestinal health and gut barrier support. Additionally, BPC-157 appears in longevity-oriented treatment discussions, though evidence for systemic anti-aging effects is preliminary at best. Anyone considering BPC-157 for any health goal should understand that its efficacy for these purposes has not been established through FDA-approved clinical trials.
How Clinics May Offer BPC-157 Therapy
Peptide therapy clinics that include BPC-157 in their protocols typically prescribe it through licensed compounding pharmacies. The most common administration route is subcutaneous injection, though some clinics offer oral capsule formulations. A standard clinical protocol generally involves an initial medical evaluation including relevant lab work, followed by a prescribed dosing regimen with periodic follow-up. Treatment duration varies by provider and clinical indication, commonly ranging from four to twelve weeks. Reputable clinics will source BPC-157 from FDA-registered compounding pharmacies that provide certificates of analysis verifying peptide purity and potency.
Safety and Regulatory Status
BPC-157 is not FDA-approved for any medical indication. It is classified as a research peptide and, when used clinically, is typically prescribed off-label by physicians through compounding pharmacies. The safety profile of BPC-157 in humans is not well established due to the lack of large clinical trials. Most safety data comes from animal studies, which have generally reported favorable tolerability at the doses studied. However, the absence of rigorous human safety data means that potential risks, drug interactions, and long-term effects remain largely unknown. Patients should be aware that compounded peptides are not subject to the same regulatory oversight as FDA-approved medications. The FDA has issued guidance regarding certain compounded peptides, and the regulatory environment continues to evolve.
Comparison with Related Peptides
BPC-157 is frequently compared to TB-500 (thymosin beta-4 fragment), another peptide studied for tissue repair and recovery. While both are discussed in recovery contexts, they operate through different proposed mechanisms. TB-500 is primarily associated with actin regulation and cell migration, whereas BPC-157 research has focused on growth factor modulation and nitric oxide system interactions. Some clinical protocols combine BPC-157 and TB-500, though evidence for combination therapy is limited to anecdotal reports and clinical observation rather than controlled trials. Unlike semaglutide, which has achieved FDA approval for specific conditions, BPC-157 remains in the research phase with no approved indications. Compared to growth hormone secretagogues like ipamorelin, BPC-157 targets fundamentally different biological pathways and is studied for different therapeutic purposes.
Related Goals
Compare Related Peptides
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH) designed for sustained growth hormone elevation through extended half-life.
Ipamorelin
A selective growth hormone secretagogue peptide studied for its ability to stimulate growth hormone release with fewer side effects compared to earlier secretagogues.
Semaglutide
An FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes management and chronic weight management in eligible patients.
TB-500
A synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair, studied primarily in preclinical research.
Find Peptide Clinics Near You
Peptide Clinics in Austin — Directory & Guide
Find peptide therapy clinics in Austin, TX. Compare providers, learn about treatments, and understand what to look for in an Austin peptide clinic.
Peptide Clinics in Los Angeles — Directory & Guide
Find peptide therapy clinics in Los Angeles. Compare providers, learn about treatments, and understand what to look for in an LA peptide clinic.
Peptide Clinics in Miami — Directory & Guide
Find peptide therapy clinics in Miami, FL. Compare providers, learn about available treatments, and understand what to look for in a Miami peptide clinic.
Peptide Clinics in New York — Directory & Guide
Find peptide therapy clinics in New York City. Compare providers, learn about treatments, and understand what to look for in a NYC peptide clinic.
Peptide Clinics in Scottsdale — Directory & Guide
Find peptide therapy clinics in Scottsdale, AZ. Compare providers, learn about treatments, and understand what to look for in a Scottsdale peptide clinic.
Further Reading
How to Evaluate a Peptide Clinic — A Patient's Checklist
Learn how to evaluate peptide therapy clinics. Understand what credentials to look for, red flags to avoid, and questions to ask before starting treatment.
Peptide Legality in the United States — What You Need to Know
Understand the legal status of peptides in the United States, including FDA regulations, compounding pharmacy rules, and state-level considerations.
Peptide Therapy Explained — How It Works
Understand how peptide therapy works, what to expect from treatment, and how to evaluate whether peptide therapy may be appropriate for you.
Research Peptides vs. Prescription Peptides — Key Differences
Understand the critical differences between research peptides and prescription peptides, including safety, legality, and quality considerations.
What Are Peptides? A Beginner's Guide
Learn what peptides are, how they work in the body, and why they are gaining attention in medical research and clinical practice.
Frequently Asked Questions
What is BPC-157 used for in research?
Is BPC-157 FDA-approved?
How is BPC-157 typically administered?
What is the difference between BPC-157 and TB-500?
How long does a typical BPC-157 treatment protocol last?
Last reviewed: 3/14/2026